| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
The antiarrhythmic effect of Granulocyte colony-stimulating factor (G-CSF) on hypertrophic cardiomyopathy (HCM) has not been clarified. Salt-sensitive rats were maintained on a high-salt diet as HCM models (n=17) and a low-salt as normal heart models (NH; n=5). After the treatments with 50microg/kg (i.p.) of G-CSF (9 HCMs and 2 NHs) and vehicle (8 HCMs and 3 NHs), rapid ventricular pacing was performed to evaluate the vulnerability to VT. The G-CSF reduced inducibility of VT as compared to vehicle in HCM (1 of 9 vs. 5 of 8, p=0.03). In addition, VT was not inducible in NH treated with G-CSF, although it was inducible in 1 of 3 NHs treated with vehicle. The G-CSF increased the phosphorylated Connexin-43 level as compared to vehicle in both HCM (1.4-fold vs. 1.2-fold, p<0.01) and NH (1.4-fold vs. 1-fold, p=0.04). The G-CSF is proposed as an antiarrhythmic agent in patients with HCM, because it reduces the vulnerability to VT by up-regulating the phosphorylated Connexin-43.
|
